We are researching if a weekly GLP-1 RA study medicine can help improve symptoms of knee osteoarthritis (OA) in people living with overweight or obesity.

People living with overweight or obesity are more likely to experience knee osteoarthritis (OA). Losing just 10% of body weight has been shown to help reduce knee pain and improve knee function and is often the first treatment doctors recommend.1-3

If you decide to join the Vesper-OA 2 study, your health and knee OA symptoms will be carefully monitored. You will also receive guidance on diet, exercise, and lifestyle from a team of weight loss specialists and be given a variety of tools to support you every step of the way.

Who may participate

Each clinical trial has its own guidelines for who can participate, called eligibility criteria. Some of the eligibility criteria to participate in this clinical trial include:

Knee osteoarthritis

Have been diagnosed with knee osteoarthritis with knee pain for at least 12 weeks

Overweight or obesity

Body mass index (BMI) of 27 or higher

Diabetes

Have or have not been diagnosed with diabetes

Age

18+ years

Additional requirements apply

The study team will discuss other requirements with you and determine if you are eligible to participate in this clinical trial.

What to expect

Before you decide to join this clinical trial, the study team will perform some screening tests to see if the study is a good fit for you. 

If you meet all the requirements, your participation will last about 66 weeks with in- person or telehealth visits approximately every 4 weeks. 

During the Treatment Period, you will be randomly assigned (like pulling a number out of a hat) to receive either the study medicine or a placebo. The placebo looks like the study medicine but does not have any active ingredients in it. You will reach your target weekly dose through gradual dose escalation.

Both the study medicine and the placebo will be given as an injection under the skin. You, or a caregiver, will be instructed on how to give the injections at home. 

After you finish the Treatment Period, you will have 2 additional follow-up visits.

Length of study treatment

52 weeks

Number of study visits

About 14 in-person visits and 4 telehealth visits

Study-related costs

No cost to participate, and health insurance is not required

About the study medicine

The study medicine is a GLP-1 RA (glucagon-like peptide-1 receptor agonist). It mimics the effects of a hormone in your body called GLP-1 that helps control your appetite and blood sugar. Along with a healthy diet and exercise, it may help people lose weight by: 

  • Increasing a feeling of fullness after eating
  • Slowing down digestion
  • Reducing appetite
  • Regulating blood sugar levels

Why this clinical trial is important

For many people, finding solutions to manage their weight and knee OA symptoms can be a challenge. We are committed to advancing research that may expand weight management treatment options for people living with knee OA and overweight or obesity. 

Many factors—including age, overall health, lifestyle, and individual differences—can affect weight management and how a person responds to potential treatment. That’s why it’s important for this clinical trial to include people from a wide range of backgrounds. This will help researchers better understand the study medicine and how it may work for different people. 

Your participation and commitment could make a difference for people looking for treatment options to help manage their weight and improve their knee OA symptoms.

About knee osteoarthritis

Osteoarthritis (OA) is a common joint disease that happens when cartilage (the soft tissue in between the bones) in joints breaks down. This leads to bones rubbing against each other, which causes inflammation. Knee OA is caused by a number of things, such as aging, genetics, knee injuries, and repetitive stress on the knee joint. Symptoms of knee OA include pain, stiffness, swelling, difficulty bending the knee joint, and feeling the knee is unstable. While there is no cure for knee OA, there are various treatments available to help manage symptoms, improve knee joint function, and slow disease progress 

Weight plays an important role in managing knee OA. Excess body weight puts more strain on knee joints. Losing even a small amount of weight can lower the stress on your knees. Decreasing that stress can reduce inflammation, lessen pain, improve movement, and slow down further knee damage.

Man and woman walk outside – Pfizer Clinical Trials
Discover locations for this study
Discover
References
  1.  Atukorala I, Makovey J, Lawler L, et al. Is there a dose response relationship between weight loss and symptom improvement in persons with knee osteoarthritis? Arthritis Care Res. 2016;68(8):1106-1114. doi: 10.1002/acr.22805. 
  2. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-474. doi:10.1002/acr.21596
  3. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: The IDEA Randomized Clinical Trial. JAMA. 2013;310(12):1263-1273. doi:10.1001/jama.2013.277669

Continue exploring

How clinical trials work

Protecting your safety & privacy

Steps to join a clinical trial

FAQs